European Pharmaceutical Review

OCTOBER 20, 2022

In recent years there has been significant development within the cell therapy field, as chimeric antigen receptor (CAR) T-cell therapy demonstrated an ability to transform the treatment of patients with haematological malignancies. What are Tregs and how are they applicable to immune-mediated disease?

Engineering 124

Engineering Side effects Manufacturing Patients 124

pharmaphorum

SEPTEMBER 11, 2022

A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at improving progression-free survival than Bristol-Myers Squibb’s immunotherapy Yervoy in patients with advanced melanoma.

Side effects 98

Side effects Patients Engineering Management 98

European Pharmaceutical Review

AUGUST 25, 2022

However, patient survival rates remain low, with the standard of care delivering a progression?free Upon diagnosis, initial treatment consists of debulking the tumour via surgical resection; however, the location of the tumour dictates the effectiveness of this tactic. It is also the most common primary brain tumour found in adults.

Side effects 99

Side effects Safety Patients Engineering 99

PM360

JULY 13, 2023

Using this flexible platform, Ambrx is developing engineered precision biologics with site-specific, homogenous, and stable conjugation to overcome limitations of traditional ADC technologies. Cellectis is pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients.

Patients 98

Patients Engineering Side effects Leads 98

Pharma Marketing Network

JULY 19, 2023

This blog post could provide information about the drug’s potential benefits, its side effects, and how it compares to other drugs on the market. This information could be valuable to potential patients who are considering taking the drug, and it could help the company attract new leads.

Marketing 98

Marketing Pharmaceutical Sales Education 98

European Pharmaceutical Review

MARCH 24, 2023

It was engineered using a unique, proprietary glycoPEGylated technology to prolong the biological activity (half-life), while maintaining the efficacy of native FGF21, a metabolic hormone. Pegozafermin also has a favourable safety and tolerability profile, with few gastrointestinal (GI) side effects.

Medical 85

Medical Side effects Safety Pharmaceutical 85

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 78

Food and Drug Administration Safety Patients Leads 78